« Back to Record
Citation APA

Goss, P. E., Smith, I., O'Shaughnessy, J., Ejlertsen, B., Kaufmann, M., Boyle, F., Buzdar, A., Fumoleau, P., Gradishar, W., Martin, M., Moy, B., Piccart-Gebhart, M., Pritchard, K., Lindquist, D., Chavarri-Guerra, Y., Aktan, G., Rappold, E., Williams, L. L., & Finkelstein, D. D. (2013). Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial. Lancet oncology, 14(1), 88-96. doi:10.1016/S1470-2045(12)70508-9


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/188911

Goss, P. E., Smith, I., O'Shaughnessy, J., Ejlertsen, B., Kaufmann, M., Boyle, F., Buzdar, A., Fumoleau, P., Gradishar, W., Martin, M., Moy, B., Piccart-Gebhart, M., Pritchard, K., Lindquist, D., Chavarri-Guerra, Y., Aktan, G., Rappold, E., Williams, L. L., & Finkelstein, D. D. (2013). Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial. Lancet oncology, 14(1), 88-96. doi:10.1016/S1470-2045(12)70508-9